Q1 Earnings Forecast for Liquidia Issued By HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Liquidia in a report issued on Thursday, March 20th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.49) per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.07) EPS.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

A number of other brokerages also recently weighed in on LQDA. Wells Fargo & Company began coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Scotiabank lifted their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Thursday, March 20th. Finally, Needham & Company LLC increased their price objective on shares of Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $26.63.

Liquidia Stock Performance

LQDA opened at $15.60 on Monday. Liquidia has a 1-year low of $8.26 and a 1-year high of $16.81. The company has a 50-day moving average of $14.95 and a 200-day moving average of $12.32. The company has a market capitalization of $1.33 billion, a P/E ratio of -9.57 and a beta of 0.07.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. LM Advisors LLC purchased a new position in Liquidia during the 4th quarter valued at about $25,948,000. Whitefort Capital Management LP boosted its holdings in shares of Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after purchasing an additional 927,546 shares during the period. Invesco Ltd. grew its position in Liquidia by 2,675.0% during the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock valued at $8,234,000 after purchasing an additional 674,940 shares in the last quarter. Janus Henderson Group PLC increased its stake in Liquidia by 1,484.5% in the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock valued at $6,293,000 after buying an additional 501,752 shares during the period. Finally, Mirabella Financial Services LLP purchased a new stake in Liquidia in the 4th quarter worth approximately $5,880,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Liquidia

In related news, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the completion of the transaction, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at $12,005,905.06. This represents a 2.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 over the last three months. Company insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).